Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
P/B ratio for Sio Gene Therapies Inc. (SIOX)
P/B ratio as of 2022: 0.81
According to Sio Gene Therapies Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.81. At the end of 2021 the company had a P/B ratio of 1.10.
P/B ratio history for Sio Gene Therapies Inc. from 2015 to 2022
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2022 | 0.81 |
| 2021 | 1.10 |
| 2020 | 0.98 |
| 2019 | 2.89 |
| 2018 | 2.00 |
| 2017 | 11.87 |
| 2016 | 4.07 |
| 2015 | -364.41 |